PBSVOTCServices-Management Consulting ServicesFiscal year ends October 31

Pharma-Bio Serv, Inc.

Financials through Q3 FY2026, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 14, 2026

$0.48+0.08 (+20.00%)

Close on Oct 19, 2026

Market cap: $11.00M
P/E (TTM): 48.0
Dividend yield: –

Debt

Borrowings on the balance sheet, Jul 31, 2026

Pharma-Bio Serv reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Pharma-Bio Serv's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Pharma-Bio Serv's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PBSV.

Revenue growth3.3% · median 2.3%

Gross margin32.3% · median 36.0%

Operating margin-1.6% · median -99.0%

Net margin2.7% · median -105.1%

Company	Revenue	Growth
CISO	$24.74M	-14.1%
RTB	$10.44M	+18.7%
PBSV	$9.48M	+3.3%
RYOJ	–	–
ROMA	–	–
EGG	–	–

Company

Next earnings (est.): Jan 28, 2027, during market hours
Exchange: OTC
Industry: Services-Management Consulting Services
Fiscal year ends: October 31
Employees: 190
Auditor: CROWE PR PSC
SEC CIK: 1304161

Advertisement
300 × 250